Clinical Trials | March 24, 2026
Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
The company plans to submit the vaccine for regulatory review
The company plans to submit the vaccine for regulatory review
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
The initial consideration for the transaction is US$ 12 million
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
Subscribe To Our Newsletter & Stay Updated
